Introduction {#section1-2192568218755684}
============

Spine surgeries are among the most common procedures to cause severe postoperative pain.^[@bibr1-2192568218755684]^ Local tissue trauma---including damage to the vertebrae, intervertebral discs, and nerve root sleeves---generate complex neuropathic and nociceptive signals that can prolong the sensation of pain well throughout the postoperative recovery period.^[@bibr2-2192568218755684]^ Inadequate pain control can contribute to longer hospital stays and potentially increase the risk of postoperative complications secondary to immobilization, such as deep vein thrombosis, pulmonary emboli, and sepsis.^[@bibr3-2192568218755684]^ Providing effective postoperative analgesia can therefore promote early mobilization and reduce many hospital-related adverse events (AEs).^[@bibr4-2192568218755684]^

Despite advancements in pain management regimens across the United States, differences of opinion continue to exist regarding optimal treatment plans for controlling postoperative pain.^[@bibr5-2192568218755684]^ Common therapies include the use of nonsteroidal anti-inflammatory drugs, acetaminophen, and corticosteroids, often used separately or in combination with one another to achieve adequate analgesia.^[@bibr6-2192568218755684]^ The cornerstone of pain control therapy, however, has traditionally been opiate analgesics due to their effectiveness in providing rapid pain relief following complex operative procedures.^[@bibr7-2192568218755684]^ Yet such analgesics are also known to cause many opioid-related AEs (or ORAEs), such as nausea, constipation, and emesis.^[@bibr8-2192568218755684],[@bibr9-2192568218755684]^ The severity of these and many other ORAEs have ultimately driven the development of novel therapies with the goal of achieving adequate analgesia and healing in the postoperative period.^[@bibr10-2192568218755684]^

In 2011, liposomal bupivacaine (LB) was approved by the US Food and Drug Administration for the exclusive use of single-dose infiltrations into the surgical site.^[@bibr11-2192568218755684]^ The extended release formulation has been shown to provide postoperative analgesia for up to 72 hours and reduce patient pain scores after various surgical procedures.^[@bibr12-2192568218755684],[@bibr13-2192568218755684]^ It is for these reasons that LB has been incorporated into current multimodal pain control protocols alongside attempts to determine its most predictable side effects.^[@bibr14-2192568218755684]^ Recent clinical trials have reported emesis, nausea, constipation, pyrexia, headaches, and dizziness to be the most common, with hypotension and bradycardia being cited as the most severe.^[@bibr15-2192568218755684],[@bibr16-2192568218755684]^

In light of these recent findings, attempts have been made to thoroughly review the safety profile of LB in order to determine its optimal utilization.^[@bibr17-2192568218755684]^ In 2014, Portillo et al sought to compare the AEs of LB with a placebo or control drug, and determined that it is relatively safe to use in therapeutic doses.^[@bibr18-2192568218755684]^ In 2016, Grieff et al assessed the efficacy of LB versus bupivacaine HCl in the postoperative management of cervical or lumbar decompression surgeries.^[@bibr19-2192568218755684]^ They mentioned that the medication did not significantly reduce AEs postoperatively; however, neither the type of side effect, nor risk of acquiring them, were discussed. Since the safety of LB has never been thoroughly evaluated in patients undergoing lumbar spine surgery, we attempted to evaluate the incidence and relative risk of AEs among patients receiving LB compared with those receiving only saline injections, in a cohort undergoing posterior laminectomy and instrumented spinal fusion surgery. A secondary aim was to assess the hospital length of stay between both groups.

Methods {#section2-2192568218755684}
=======

Study Design {#section3-2192568218755684}
------------

After obtaining institutional review board approval, 59 patients were enrolled in a prospective randomized control trial from August 2015 to October 2016. Candidates for the study were patients 18 years of age or older undergoing a primary, 1- or 2-level elective open posterior lumbar decompression and instrumented fusion for degenerative spondylosis. Patients were included if they had any number of laminectomies, a 1- or 2-level fusion, with at least 1 level involving a lumbar vertebrae. Patients were excluded if they had an active infection, metastatic malignancy of the spine, fracture of a lumbar vertebrae, history of substance abuse, impaired cardiovascular function, or severe hepatic disease. All procedures were performed by 4 fellowship-trained orthopedic spine surgeons at a tertiary referral center. All procedures included decompression plus or minus medial facetectomies and foraminotomies, as well as posterior instrumentation with pedicle screws and rod constructs. Fusion techniques included posterolateral, posterior lumbar interbody, and transforaminal interbody fusions with local bone autograft, morselized allograft bone, and/or demineralized bone matrix in any combination.

Patients were randomized in a 1:1 fashion by our hospital research pharmacy to ensure that they were equally allocated to either a treatment or control group. Computer randomization was used to assign patients in their respective groups. Depending on the patients' random assignment, the research pharmacy staff delivered either LB or the placebo medication to the operating room. The treatment arm received 266 mg of LB in a 60 mL suspension, while the control group received 60 mL of 0.9% sterile saline. Local injections were made prior to wound closure into the exposed paraspinal muscles and surrounding soft tissues, as similarly performed by Grieff and colleagues.^[@bibr19-2192568218755684]^ Due to the noticeable appearance of LB suspension compared with placebo saline, research staff and investigators administering the injections were not blinded to patient group assignments. All other providers involved in postoperative care including nurses, pain management team members, and physical therapists were blinded to patient group assignments. All patients had a patient-controlled analgesia pump initiated shortly after surgery that was discontinued at 6 [am]{.smallcaps} on postoperative day 1. Intravenous and oral (PO) opioid-based pain medications were used only as necessary for adequate pain control throughout the postoperative period in conjunction with other nonopioid medications.

Data Collection and Statistical Analysis {#section4-2192568218755684}
----------------------------------------

Cumulative data was entered into an electronic data sheet (Microsoft Excel, Microsoft Office, Redmond, WA). Demographic data included age, sex, body mass index, and Charlson Comorbidity Index scores.^[@bibr20-2192568218755684]^ Surgical data included operation length (minutes), estimated blood loss, and number of vertebra levels decompressed and fused. The primary outcome measured was the incidence of postoperative AEs that occurred between the treatment and control groups. For the purpose of this study, an AE was defined as any undesired event occurring within 72 hours, postoperatively. A literature review of published randomized controlled trials was conducted to identify a list of common AEs of LB ([Table 2](#table2-2192568218755684){ref-type="table"}).^[@bibr18-2192568218755684]^ Data regarding hospital length of stay was collected from the day of admission until the patient was successfully discharged.

###### 

Patient Characteristics^a^.

![](10.1177_2192568218755684-table1)

                                     Liposomal Bupivacaine Group (N = 33)   Control Group (N = 26)   *P*
  ---------------------------------- -------------------------------------- ------------------------ ------
  Male: female                       21:12                                  9:17                     .652
  Age                                59.8 (12.22)                           63.1 (10.6)              .271
  BMI                                29.9 (6.38)                            30.5 (6.3)               .736
  CCI scores                         3.0 (0.39)                             2.5 (0.37)               .29
  Length of stay (days)              3.9 (1.62)                             3.9 (1.46)               .92
  Number of vertebrae fused          2.7 (1.0)                              2.4 (0.50)               .093
  Number of vertebrae decompressed   3.1 (1.0)                              3.7 (0.91)               .036
  EBL (mL)                           428.9 (337.7)                          450.9 (262.5)            .780
  Operation length (minutes)         147.4 (54.3)                           168.7 (56.2)             .161

Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index^[@bibr20-2192568218755684]^; EBL, estimated blood loss.

^a^Values presented as means (SDs).

###### 

Adverse Events^a^.

![](10.1177_2192568218755684-table2)

                               Liposomal Bupivacaine Group (N = 33)   Control Group (N = 26)   *P*
  ---------------------------- -------------------------------------- ------------------------ -------
  Nausea                       13 (39.3)                              6 (23.0)                 .263
  Vomiting                     6 (18.1)                               2 (7.6)                  .445
  Constipation                 5 (15.1)                               5 (19.2)                 .736
  Urinary retention            4 (12.1)                               4 (15.3)                 .721
  Hypotension                  6 (18.1)                               4 (15.3)                 1.000
  Arrhythmias                  0 (0)                                  0 (0)                    ---
  Pruritus                     4 (12.1)                               4 (15.3)                 .721
  Headache                     3 (9.0)                                1 (3.8)                  .623
  Acute mountain sickness      1 (3.0)                                0 (0)                    1.00
  Acute respiratory distress   0 (0)                                  0 (0)                    ---
  Desaturation                 1 (3.0)                                0 (0)                    1.00
  Pyrexia                      1 (3.0)                                0 (0)                    1.00

^a^Values presented as n (%).

Statistical analysis was done with the aid of JMP Pro Version 13 STATS Software (SAS Institute Inc, Cary, NC). Statistical tests that were performed included a 2-tailed Fischer's exact test for proportional differences in dichotomous variables and a 2-tailed student *t* test for the means of normally distributed continuous variables. Nonparametric data means were compared using the Wilcoxon rank sum test. An α error of 5% was set as the threshold for significance for all tests.

Results {#section5-2192568218755684}
=======

A total of 59 patients were enrolled in this study with 33 patients randomized to the treatment group and 26 patients randomized to the control group. Both groups were similar with regard to age, sex, body mass index, and Charlson Comorbidity Index scores^[@bibr20-2192568218755684]^ ([Table 1](#table1-2192568218755684){ref-type="table"}). With regard to surgical parameters, there was no difference in operation length, number of vertebrae fused, and estimated blood loss between the treatment and control group ([Table 1](#table1-2192568218755684){ref-type="table"}).

A list of AEs between the treatment and control groups is shown in [Table 2](#table2-2192568218755684){ref-type="table"}. The most common AEs in the treatment group were nausea (39.3%), emesis (18.1%), hypotension (18.1%), constipation (15.1%), urinary retention (12.1%), and pruritus (12.1%). With regard to the control group, the most common AEs were nausea (23%), constipation (19.2%), urinary retention (15.3%), hypotension (15.3%), and pruritus (15.3%). No significant difference in the rates of AEs was appreciated between both groups.

Patients who received LB intraoperatively had an increased risk of developing nausea (relative risk \[RR\] = 1.7; 95% confidence interval \[CI\] = 0.75-3.8), vomiting (RR = 2.3; 95% CI = 0.51-10.7), and headaches (RR = 2.36; 95% CI = 0.26-21.4). Patients receiving LB had a decreased risk of developing constipation (RR = 0.78; 95% CI = 0.25-2.43), urinary retention (RR = 0.78; 95% CI = 0.21-2.85), and pruritus (RR = 0.78; 95% CI = 0.21-2.8) postoperatively. Relative risk values failed to reach statistical significance. With regard to the secondary outcome measure, there was no statistically significant difference in the hospital length of stay between the treatment and control groups (3.9 vs 3.9 days; *P* = .92).

Discussion {#section6-2192568218755684}
==========

Complex spine surgeries often involve extensive trauma to underlying musculoskeletal and periarticular tissues of the spine. The degree of postoperative pain during the recovery process is difficult to manage without the use of potent analgesics.^[@bibr21-2192568218755684],[@bibr22-2192568218755684]^ This has chiefly driven the consumption of large amounts of opioids among patients, protracting their in-hospital length of stay, as well as burdening them with many deleterious and costly AEs.^[@bibr7-2192568218755684]^ In an effort to address, and possibly resolve, the many complications associated with opioid use, current therapeutic strategies now endorse a multimodal approach to postoperative pain control. The regimen includes the use of nonopioid analgesics and local anesthetics, such as LB.^[@bibr23-2192568218755684]^ The latter has been of particular interest since its approval as an infiltrative anesthetic by the Food and Drug Administration in 2011.^[@bibr11-2192568218755684],[@bibr24-2192568218755684]^ With a single administration given during surgery, the newly extended release formulation may prolong analgesia and possibly limit opioid dependence in the postoperative period.^[@bibr15-2192568218755684],[@bibr25-2192568218755684]^ Both LB and bupivacaine HCl are contraindicated in obstetrical paracervical block anesthesia, since the latter has been shown to result in fetal bradycardia and death.^[@bibr11-2192568218755684]^

Recent studies have also demonstrated a favorable safety profile of LB when used within therapeutic doses in the setting of various surgical procedures, including inguinal hernia repair, total knee arthroplasty, hemorrhoidectomy, breast augmentation, and bunionectomy.^[@bibr26-2192568218755684]^ And while it has been shown that LB did not significantly reduce AEs following cervical or lumbar decompression surgery,^[@bibr19-2192568218755684]^ no study has thoroughly examined the safety profile of LB in the exclusive setting of operative lumbar spine procedures. The primary purpose of this study was to therefore determine the incidence and risk of AEs among patients receiving LB compared with those receiving only saline injections, in the setting of posterior laminectomy and instrumented spinal fusion surgery. A secondary aim was to assess the hospital length of stay between both groups.

With regard to the treatment group, our results demonstrate the most common AE to be nausea, followed by emesis or hypotension (both having the same incidence), constipation, urinary retention, and pruritus. A relatively similar incidence of AEs was found in the control group, with nausea likewise being the most common, followed by constipation, urinary retention, hypotension, and pruritus. When comparing the rates of AEs between both groups, however, no statistically significant difference was found. Despite these findings, our results slightly mirror those of previous reports involving the use of LB (≤266 mg) in nonspinal procedures; the majority revealed nausea to be the most common AE experienced in the postoperative period, followed by constipation, emesis, and pyrexia.^[@bibr18-2192568218755684],[@bibr26-2192568218755684]^ Since many of these AEs have been firmly grounded in studies assessing the exclusive use of opioids, and considering that all patients had access to a controlled analgesic pump, it is likely that most of these events are related to the perioperative and postoperative use of general anesthetic medicines and opioids.^[@bibr9-2192568218755684],[@bibr27-2192568218755684]^ Our findings further reveal that the intraoperative administration of LB neither increased nor decreased the relative risk of developing any of the above-mentioned AEs, nor had any significant effect on the hospital length of stay for patients undergoing spine surgery. The presence and severity of certain comorbidities, in addition to the postoperative use of other analgesics, may likely hinder attempts at discerning the unequivocal impact of LB in spine surgery.

To our knowledge, this report serves as the first randomized prospective trial assessing the safety profile of LB in spine surgery. However, several limitations still challenge our analysis. The number of patients randomized to this study was relatively small (n = 59), which may obscure relevant findings across the treatment and control groups. Controlling the study population more strictly by including 1-level, rather than 1- or 2-level, posterior lumbar decompression and fusion surgeries would also reveal more clearly the postoperative safety profile of LB. In addition to the impact of patients' preoperative narcotic requirements on their postoperative course, the co-administration of other postoperative medications, such as sedatives, antispasmodics, or anticholinergics, many of which have been shown to augment the incidences of ORAEs, makes it particularly difficult in determining any association between the use of LB and the outcomes studied. This is further compounded by our study design wherein only single-dose injections of LB were directly administered to the surgical site. Last, preexisting comorbidities and other concomitant medications may potentiate the rate and risk of developing any of the AEs, further stressing the need to adjust for independent and combined variables that could affect primary and secondary outcomes, such as hospital length of stay and patient readmission rates. Since this study focused on the safety profile of LB, it is also difficult to assess whether the medication be recommended for relieving postoperative pain following lumbar spine surgery. In summary, a robustly powered, randomized double-blind prospective study with a larger sample size will be necessary in order to identify meaningful associations between LB and the incidence of AEs in patients undergoing spine surgery.

Conclusion {#section7-2192568218755684}
==========

In this prospective randomized pilot study of 59 patients who underwent posterior laminectomy and instrumented spinal fusion surgery, single-dose injections of LB into the surgical site prior to wound closure did not significantly increase or decrease the incidence and risk of developing AEs in the immediate postoperative period, nor had any significant effect on the hospital length of stay. To better assess the safety profile of LB in spine surgery, carefully designed studies involving a larger sample size are warranted.
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